KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q3 2025 value amounting to -$0.16.

  • Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) fell 12909.09% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.67, marking a year-over-year increase of 6084.34%. This contributed to the annual value of $2.17 for FY2024, which is 14942.68% up from last year.
  • Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) amounted to -$0.16 in Q3 2025, which was down 12909.09% from $1.23 recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) peaked at $1.23 during Q2 2025, and registered a low of -$0.32 during Q4 2021.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $0.21 (2023), whereas its average is $0.29.
  • Per our database at Business Quant, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) tumbled by 39090.91% in 2021 and then soared by 768887.55% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.32 in 2021, then soared by 99.59% to -$0.0 in 2022, then skyrocketed by 7688.88% to $0.1 in 2023, then surged by 535.17% to $0.64 in 2024, then tumbled by 125.19% to -$0.16 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.16 for Q3 2025, versus $1.23 for Q2 2025 and $0.95 for Q1 2025.